New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, Sep 30, 2026

Shareholders’ equity is 88.2% of the balance sheet. What is a balance sheet?

Sep 30, 2026 · total $649.3M

Owns

$45.2MLong-term assets
$12.7MOther short-term assets
$591.4MCash & all investments

Funded by

$572.5MShareholders’ equity
$76.7MOther liabilities

Debt is 0.00% of the total; shareholders’ equity 88.2%.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Total current assets
345.35 298.13 610.16 484.46
Total non-current assets
45.59 50.06 111.62 164.79
Total Assets
390.94 348.19 721.79 649.25
Total current liabilities
37.54 31.67 70.00 45.62
Total non-current liabilities
603.74 617.15 36.26 31.12
Total liabilities
641.28 648.82 106.26 76.73
Common Equity (Total)
(250.33) (300.63) 615.52 572.52
Shareholders Equity (Total)
(250.33) (300.63) 615.52 572.52

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026